Psychotomimetism: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 30: | Line 30: | ||
[[Category:Hallucinogens]] | [[Category:Hallucinogens]] | ||
[[Category:Dissociative drugs]] | [[Category:Dissociative drugs]] | ||
{{No image}} | |||
__NOINDEX__ | |||
Latest revision as of 00:11, 18 March 2025
Psychotomimetism is a term used in psychopharmacology to describe the effects of certain drugs that mimic the symptoms of psychosis, including hallucinations, delusions, and disordered thinking. The term is derived from the Greek words "psyche" (mind) and "mimesis" (imitation).
History[edit]
The term "psychotomimetic" was coined by the psychiatrist Louis Jolyon West in 1954 to describe the effects of the drug LSD. West was interested in the potential of LSD and similar drugs to produce a temporary state of psychosis in healthy individuals, which could then be studied to gain insights into the nature of psychotic disorders.
Drugs[edit]
Drugs that are considered psychotomimetic include hallucinogens such as LSD, psilocybin, and mescaline, as well as dissociative drugs like ketamine and phencyclidine (PCP). These drugs can produce a wide range of effects, including perceptual distortions, hallucinations, delusions, and cognitive impairment.
Research[edit]
Research into psychotomimetic drugs has provided valuable insights into the neurobiology of psychosis. For example, studies have shown that these drugs can induce changes in brain activity that are similar to those seen in individuals with schizophrenia and other psychotic disorders. This has led to the development of new theories about the underlying causes of these disorders, as well as new approaches to treatment.
See also[edit]
References[edit]
<references />


